¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
1/22 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2021-01-22
Á¶È¸¼ö
322


¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù. 

À̹øÁÖ Åä¿äÀÏ¿¡ ¹ßÇ¥µå¸± ³í¹®ÀÇ Á¦¸ñÀº

"Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy"

À̸ç À̹ø´Þ¿¡ Advanced science ¿¡ ÃâÆÇµÈ ³í¹®ÀÔ´Ï´Ù. 
PEI¸¦ ±â¹ÝÀ¸·Î PEGlyationÀ» ÅëÇØ µ¶¼ºÀ» ÃÖ¼ÒÈ­ÇÏ°í, neoantigenÀ» °áÇÕ½ÃŲ ³ª³ë Àü´Þü¿¡ CpG¸¦ simple assembly ÇÏ¿© Æ©¸Ó ¹é½ÅÀ¸·Î Àû¿ëÇÑ ½ºÅ͵ðÀÔ´Ï´Ù. 
ÃÖ±Ù Ç×¾Ï Ä¡·áÁ¦ ¹× ´Ù¾çÇÑ ¹ÙÀÌ·¯½º ¹é½Å°ú °ü·ÃÇÏ¿©, PST ȤÀº PEI¸¦ ±â¹ÝÀ¸·ÎÇÑ adjuvant¸¦ ÀÌ¿ëÇÑ ¿¬±¸¸¦ »ý°¢Çغ¸°í °øºÎ¸¦ ÇÏ´ø Áß¿¡ 
¹ßÇ¥¸¦ Çϸé ÁÁÀ» °Í °°¾Æ¼­ ¼±Á¤À» Çß½À´Ï´Ù. 
ÇØ´ç ³í¹®¿¡¼­ Á¦°¡ ÇÏ°íÀÖ´Â Æ©¸Ó ½ºÅ͵𿡼­ Ãß°¡µÇ¸é ÁÁÀº ½ÇÇèµéÀÌ ÀÖ¾î, À̸¦ °ð ¼öÇàÇÏ°íÀÚÇϸç, 
ÇâÈÄ ÁøÇà µÉ ¹é½Å ½ºÅ͵ð ¹× Ç×¾Ï ½ºÅ͵𿡼­ PST ȤÀº PEI¸¦ ±â¹ÝÀ¸·Î ÇÑ adjuvant¸¦ Á¦½ÃÇغ¸°íÀÚ ÇÕ´Ï´Ù. 

³í¹® ¸µÅ© : https://doi.org/10.1002/advs.202002577

÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
1/22 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, ³ª·¡ÀÔ´Ï´Ù. Á¦°¡ À̹øÁÖ¿¡ ¹ßÇ¥ÇÏ°Ô µÉ ³í¹®Àº 2018³â immunity¿¡ °³Á¦µÈ "B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen"À̶ó´Â Á¦¸ñÀÇ ³í¹®À¸·Î, antigenÀÌ virus like particle(VLP)ÀÏ..
ÀÌÀü±Û
1/16 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ±è¼öÁöÀÔ´Ï´Ù. Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº2017³â JI ¿¡ ÃâÆÇ µÈ "T Cell–Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide ofStreptococcus pneumoniae" ÀÔ´Ï´Ù. model glycoconjugate vaccineÀÌ adaptive immune system À» È°¼ºÈ­½Ãų ¼ö ÀÖ´Â mechanism¿¡..